EUVIMEDEUVIMED entdecken
Crossref

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial

Delphine Salfati, Margaux Huot, Thomas Aparicio, Come Lepage, Julien Taieb, Olivier Bouché, Valérie Boige, Jean-Marc Phelip, Laetitia Dahan, Jaafar Bennouna, Karine Le Malicot, Olayide Boussari und 1 weitere

Digestive and Liver Disease · 2023-06 · 55 (6) · 791-798

DOI: 10.1016/j.dld.2022.12.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2023-06. Verfasst von Delphine Salfati und 12 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, Université de Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To examine the relationship between carcinoembryonic antigen (CEA) kinetics and prognosis in metastatic colorectal cancer (mCRC) patients receiving first-line chemotherapy in the PRODIGE9 trial. METHODS: Associations between monthly CEA measurements within 6 months since baseline and progression-free survival (PFS) were evaluated using a joint-latent class-mixed model. A validation set was used to test our prognosis model. Correlations between CEA trajectories (classes) and baseline characteristics were also investigated. RESULTS: Three classes were identified. Class 1 had low baseline CEA with small variations. Class 2 had high baseline CEA with a rapid decrease reaching the same CEA level at 6 months as in class 1. Class 3 had high baseline CEA with a transient decrease followed by an increase to reach, at 6 months, the same CEA level as at baseline. Six-month PFS was significantly lower in class 3 than in classes 1 and 2 (57% vs. 91% and 93% respectively; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansCarcinoembryonic AntigenPrognosisBiomarkers, Tumor

Stichwörter der Autor:innen

Carcinoembryonic antigenMetastatic colorectal cancerPrognostic biomarker

Substanzen

Carcinoembryonic AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Assistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, Université de Paris Cité, Paris, France.
  • FFCD, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM, Paris, France.
  • Department of Gastroenterology and Digestive Oncology, CHU Reims, Université de Reims Champagne-Ardenne (URCA), Reims, France.
  • Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay Villejuif, France.
  • Department of Gastroenterology and Digestive Oncology, University Hospital of Saint Etienne, Saint Etienne, France.

Zitieren

APA

Salfati, D., Huot, M., Aparicio, T., Lepage, C., Taieb, J., Bouché, O., Boige, V., Phelip, J. M., Dahan, L., Bennouna, J., Le Malicot, K., Boussari, O., & Gornet, J. M. (2023). Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial. Digestive and Liver Disease, 55(6), 791-798. https://doi.org/10.1016/j.dld.2022.12.018

Vancouver

Salfati D, Huot M, Aparicio T, Lepage C, Taieb J, Bouché O, et al. Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial. Digestive and Liver Disease. 2023;55(6):791-798. doi:10.1016/j.dld.2022.12.018

BibTeX
@article{Salfati2023,
  author = {Salfati, Delphine and Huot, Margaux and Aparicio, Thomas and Lepage, Come and Taieb, Julien and Bouché, Olivier and Boige, Valérie and Phelip, Jean-Marc and Dahan, Laetitia and Bennouna, Jaafar and Le Malicot, Karine and Boussari, Olayide and Gornet, Jean-Marc},
  title = {Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial},
  journal = {Digestive and Liver Disease},
  year = {2023},
  volume = {55},
  number = {6},
  pages = {791--798},
  doi = {10.1016/j.dld.2022.12.018}
}
Kostenlos starten →